P/E ratio for Omeros Corporation (OMER)
P/E ratio as of April 2024 (TTM): 4.91
According to Omeros Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 4.91406. At the end of 2022 the company had a P/E ratio of 3.01.
P/E ratio history for Omeros Corporation from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 3.01 | 44.81% |
| 2021 | 2.08 | -134.95% |
| 2020 | -5.95 | -28.16% |
| 2019 | -8.29 | 94.19% |
| 2018 | -4.27 | -74.3% |
| 2017 | -16.6 | 176.22% |
| 2016 | -6.01 | -23.56% |
| 2015 | -7.87 | -29.54% |
| 2014 | -11.2 | 35.45% |
| 2013 | -8.24 | 152.47% |
| 2012 | -3.26 | 6.6% |
| 2011 | -3.06 | -49.46% |
| 2010 | -6.06 | 380.07% |
| 2009 | -1.26 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | 111.12% | 🇺🇸 USA |
 Pfizer PFE | 13.7 | 177.78% | 🇺🇸 USA |
 Genetic Technologies GENE | N/A | N/A | 🇦🇺 Australia |
 Eterna Therapeutics ERNA | -0.3174 | -106.46% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.